The Patent Finder

Biosceptre (Aust) Pty Ltd.

23 patents currently held · Updated Nov 22, 2026
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

Previously recorded as Biosceptre International Limited (to 2016)

14
Ending by 2030
Sep 2028
Next term end

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 1 fee due Mar 8, 2027
    The maintenance fee for Anti P2X7 Receptor Antibodies and Fragments Thereof (US 9,127,059) comes due Mar 8, 2027. Unpaid by Sep 8, 2027, it lapses early.
  • 1 fee due May 10, 2027
    The maintenance fee for Peptides for generating an antibody selectively binding to a non-ATP-binding P2X7 receptor but not to an ATP-binding P2X7 receptor (US 9,181,320) comes due May 10, 2027. Unpaid by Nov 10, 2027, it lapses early.
  • 1 fee due Jul 28, 2027
    The maintenance fee for Combination therapy utilizing P2X7 peptides (US 10,543,262) comes due Jul 28, 2027. Unpaid by Jan 28, 2028, it lapses early.
  • 1 fee due Sep 24, 2027
    The maintenance fee for Methods of treating cancer with a P2X7 peptide (US 10,597,451) comes due Sep 24, 2027. Unpaid by Mar 24, 2028, it lapses early.
  • 1 fee due Nov 3, 2027
    The maintenance fee for Peptides for inducing antibodies to a non-functional P2X7 receptor (US 9,328,155) comes due Nov 3, 2027. Unpaid by May 3, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

Nothing was recorded against this company's patents in the last 90 days.

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleStatus Expires Confidence
US 8,658,385Purinergic (P2X) Receptors in Extra-Cellular Body Fluid
In force
 · High confidence
In forceHigh confidence
US 9,181,320Peptides for generating an antibody selectively binding to a non-ATP-binding P2X7 receptor but not to an ATP-binding P2X7 receptor
In force
 · USPTO record
In forceUSPTO record
US 9,944,701Methods of treating cancer with antibodies that bind P2X7 receptors
In force
 · USPTO record
In forceUSPTO record
US 10,597,451Methods of treating cancer with a P2X7 peptide
In force
 · USPTO record
In forceUSPTO record
US 8,293,491Purinergic (P2X) Receptors in Extra-Cellular Body Fluid
In force
 · High confidence
In forceHigh confidence
US 8,440,186P2X7 epitopes
In force
 · USPTO record
In forceUSPTO record
US 8,597,643Antibodies for binding to non-functional P2X7 receptors in trimeric form
In force
 · USPTO record
In forceUSPTO record
US 9,328,155Peptides for inducing antibodies to a non-functional P2X7 receptor
In force
 · USPTO record
In forceUSPTO record
US 10,238,716Anti- P2X7 Peptides and Epitopes
In force
 · Medium confidence
In forceMedium confidence
US 9,688,771Anti P2X7 receptor antibodies and fragments thereof
In force
 · USPTO record
In forceUSPTO record
10 of 23 patents shown.
Pro members see all 23.
Pro members: see all 23 patents
Also on record, not counted in the 23: 8 ended at full term. List them

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

7 pending · 1 no status recorded

Showing 1 to 8 of 8, newest filing first. An application has no patent term. A term is computed when and if it grants, and appears on that patent's own page. Where no title is shown, the bulk publication record carries none and this site holds no USPTO file history for that application.

ApplicationTitleFiledStatus
18/895,282Anti P2X7 Receptor Antibodies and Fragments ThereofSep 24, 2024Pending
18/783,109Chimeric Antigen Receptors and Uses ThereofJul 24, 2024Pending
18/688,086Methods and Compositions for Stimulating Immune ActivitySep 1, 2022Pending
18/686,554Novel Dysfunctional P2X7 BindersSep 1, 2022Pending
18/285,621Methods for Controlling Immune Cell ActivityApr 8, 2022Pending
18/281,045Novel Cell Therapy SystemMar 11, 2022Pending
17/618,849P2X7 Receptor Targeted TherapyJul 24, 2020Pending
16/568,072Sep 11, 2019No status recorded
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 22, 2026 · includes USPTO assignment data published Nov 21, 2026, status data published Nov 22, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited